目的 分析2015-2017年天津医科大学代谢病医院住院药房口服降糖药的使用情况，为内分泌临床用药提供参考。方法 对2015-2017年天津医科大学代谢病医院住院药房口服降糖药的用量、销售金额、用药频度（DDDs）、日均费用（DDC））和排序比（B/A）等进行统计分析。结果 2015-2017，口服降糖药的销售金额和药品的总销售金额都有明显下降。α-糖苷酶抑制剂类药物的销售金额始终保持在首位；双胍类和磺脲类药物的销售金额、构成比和排序呈持续上升趋势，噻唑烷二酮类药物和DDP-4抑制剂类药物的构成比则处于下降趋势。阿卡波糖的销售金额和构成比分别在2015、2017年居于首位，2016年伏格列波糖的销售金额跃升为第1位。二甲双胍和伏格列波糖的DDDs连续3年排在前两位。DDC最高的是阿卡波糖；最低的是二甲双胍。2015-2017年，大部分药品的B/A值均接近于1.00，阿卡波糖的B/A值在0.50以下，而二甲双胍的B/A值在2.00以上。结论 天津医科大学代谢病医院住院药房口服降糖药的使用基本合理，符合糖尿病防治指南中的推荐，双胍类或α-葡萄糖苷酶抑制剂类为临床首选药品；受惠于新的药品价格政策，患者的用药经济负担得到减轻。

Objective To investigate the usage of oral hypoglycemic drugs in the inpatient pharmacy of Metabolic Disease Hospital of Tianjin Medical University from 2015 to 2017, in order to provide references for clinical rational drug use. Methods The amount, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of oral hypoglycemic drugs in Metabolic Disease Hospital of Tianjin Medical University from 2015 to 2017 were calculated and analyzed statistically. Results From 2015 to 2017, there was a significant decrease in consumption sums of oral hypoglycemic drugs and total drugs. Consumption sum of α-glucosidase inhibitors always ranked the first. Consumption sum, constituent ratio, and sequence of biguanides and sulfonylureas had been on a rising tendency. The constituent ratio of thiazolidinediones and DDP-4 inhibitors had the tendency of decrease. Consumption sum and constituent ratio of acarbose always ranked the first in 2015 and 2017, while consumption sum of voglibose jumped to the first place. DDDs of melbine and voglibose ranked the top two for three academic years. DDC of acarbose was the highest, while DDC of melbine was the lowest. From 2015 to 2017, B/A value of most drugs were near to 1.00. B/A value of acarbose was below than 0.50, and B/A value of melbine was above 2.00. Conclusion The application of oral hypoglycemic drugs in the inpatient pharmacy of Metabolic Disease Hospital of Tianjin Medical University from 2015 to 2017 is basically rational, which meet the recommendations of prevention guide of diabetes. Biguanides and glycosidase inhibitor are preferred in clinic. Benefiting from the drug price policy, the economic burden of drug use has been deduced.